Rallybio (RLYB) announced the initiation of dosing in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic study evaluating RLYB116, the company’s innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor. Additionally, Rallybio announced that the initial indication focus for RLYB116 will be on two hematologic conditions with significant unmet need: immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. Patients suffering from these potentially life-threatening conditions have no approved or effective therapeutic options.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLYB: